Elizabeth Yurth, M.D.

The study would have had to go out for five years.

So basically, they're still hugely beneficial for cognitive protection.

So I like them kind of, we have certainly a large number of patients, but use a low dose of a GLP-1.

You don't need a lot.

So you use a dose that you find that somebody is not losing weight and they're not nauseous and they feel fine.

And that's the dose you target in

to do all these protective effects.

And I have a lot of osteoarthritis patients.

There's great studies now on the GLP-1s and osteoarthritis.

There's great information on it for helping immune function, for helping people fight viruses.

So the GLP-1s kind of float to the top of the list.

We do make GLP, right?

That is, again, it's an innate peptide to our bodies.

And it has huge power.

including lowering inflammatory markers like what's something called NLRP3.

So we know that lowers.

So we know that we can actually, you know, once you lower inflammation, you improve immune function, you're dealing with a whole lot of the aspects of aging.

So the GLP-1s are going to kind of float to that top of the list, right?

And then it's going to be your reparative peptides, your thymic peptides, thymus alpha-1, which is known as zidaxin.

It's approved.